[1]Shihab F, Christians U, Smith L, et al. Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics,exposure-response relationships,and clinical outcomes[J].Transpl Immunol,2014,31(1):22-32.
[2]Fuchs U, Zittermann A, Ensminger SM, et al.Clinical out-come in heart recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus[J].Transpl Immunol,2014,31(2):87-91.
[3]侯乐.依维莫司治疗晚期肾癌和乳腺癌不良反应观察及护理[J].中西医结合护理,2015,1(3):13-15.
[4]Amy Purrington.自发报告安全性数据库:FDA、WHO-UMC、Eudravigilance数据库[J].中国药物警戒, 2009, 6(6):382-384.
[5]Institute of Medicine of the National Academies. The future of drug safety: promoting and protecting the health of the public[M]. Washington, DC:The National Academies Press, 2007:53,108-109.
[6]Montastruc JL, Sommet A, Bagheri H, et al.Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database[J].Br J Clin Pharmacol, 2011, 72(6):905-908.
[7]Sakaeda T, Tamon A, Kadoyama K, et al.Data mining of the public version of the FDA Adverse Event Reporting System[J].Int J Med Sci, 2013,10(7):796-803.
[8]国家药品不良反应监测年度报告(2013)http://www.sda.gov.cn/WS01/CL0078/99794.html
[9]党大胜. 药物不良反应标准术语检索数据库的建立及考察[D].第二军医大学, 2006.
[10]沈剑文. 不同专业医务人员药品不良反应志愿报告的质量与特征[D].复旦大学,2009.
[11]林伟兴,叶小飞,姚洪祥,等.药品不良反应术语集现状分析[J].中国药物警戒, 2009, 6(12):713-716.
[12]贠文博,蒋朋利,吴晶,等.阿司匹林与氯吡格雷关联使用与华法林治疗发生出血的比较研究[J].中国临床药理学与治疗学,2013,18(11):1251-1259.
[13]蒋朋利,吴晶,孙鹤. 他汀类药物的使用与认知能力下降、糖尿病及癌症之间的关系[J]. 中国临床药理学与治疗学,2014,19(10):1132-1138.
[14]贠文博.抗血栓形成药物治疗发生出血不良反应的对比研究[D].天津大学, 2012.
[15]徐红,肖寒,方乃青.乳腺癌患者口服依维莫司的不良反应及防治措施[J].现代临床护理,2016,15(12):55-58. |